Milou-Daniel Drici

Prof. Dr. Milou-Daniel Drici

Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d’Azur, France
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Therapies
Verified
Journal Article
Closed access
Alexandre O. GérardAlexandre O. Gérard
Alexandre O. Gérard
SRSerena Romani
Serena Romani
AFAudrey Fresse
Audrey Fresse
DVDelphine Viard
Delphine Viard
NPNadège Parassol
Nadège Parassol
MDMilou-Daniel Drici
Milou-Daniel Drici

31 October 2023 in Therapies
Verified
Journal Article
Closed access
ADAlexandre Destere
Alexandre Destere
DMDiane Merino
Diane Merino
TLThibaud Lavrut
Thibaud Lavrut
FRFanny Rocher
Fanny Rocher
DVDelphine Viard
Delphine Viard
AGAlexandre O. Gérard
Alexandre O. Gérard

19 December 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AGAlexandre O. Gérard
Alexandre O. Gérard
ALAudrey Laurain
Audrey Laurain
AFAudrey Fresse
Audrey Fresse
NPNadège Parassol
Nadège Parassol
MMMarine Muzzone
Marine Muzzone
MDMilou-Daniel Drici
Milou-Daniel Drici
Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID‐19). Its benefit‐risk ratio is still being explored because data in the field are rather scant. A decrease of the creatinine clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance. Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance postmarketing data. An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID‐19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir). The combination of the terms “acute renal failure” and “remdesivir” yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20‐fold (20.3; confidence interval 0.95 [15.7–26.3], P < 0.0001]) that of comparative drugs. Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID‐19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID‐19 renal function should prevail before and during treatment with remdesivir in COVID‐19.

3 May 2022 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AGAlexandre O. Gérard
Alexandre O. Gérard
Diane A. MerinoDiane A. Merino
Diane A. Merino
EOElise K. Van Obberghen
Elise K. Van Obberghen
FRFanny Rocher
Fanny Rocher
ADAlexandre Destere
Alexandre Destere
MDMilou-Daniel Drici
Milou-Daniel Drici
Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key role in the pathogenesis of migraine attacks. The deficiency of CGRP is involved in Raynaud’s phenomenon, which consists of abnormal vasoconstriction of the digits. We aimed to assess the potential association of Raynaud’s phenomenon with CGRP-targeting drugs, analyzing real-world data from the World Health Organization (VigiBase®). Methods: We queried all reports of Raynaud’s phenomenon involving a CGRP-targeting drug. We sought disproportionate reporting of Raynaud’s phenomenon with these drugs. For this purpose, we relied on the calculation of the Information Component (IC). A positive lower end of the 95% confidence interval (CI) of the IC defines a statistically significant association. As migraine patients are prone to Raynaud’s phenomenon, we also calculated the IC of Raynaud’s phenomenon with CGRP-targeting drugs compared to 5HT1B/D agonists (triptans), and beta-blockers used in the treatment of migraine. Results: Overall, 99 reports of Raynaud’s phenomenon involving CGRP-targeting drugs have been yielded in VigiBase®. The most reported CGRP-targeting drug was erenumab, with 56 reports (56.6%). The median time to onset was 84 days. No fatality was notified, but one patient suffered from gangrene and extremity necrosis. As a whole, CGRP-targeting drugs were significantly associated with Raynaud’s phenomenon, with an IC of 3.3 (95%CI: 3.0–3.5). There was a disproportionate reporting of Raynaud’s phenomenon with CGRP-targeting drugs compared to triptans (IC 0.4; 95%CI: 0.1–0.6) and to beta-blockers (IC 0.5; 95%CI: 0.2–0.7) as well. Conclusions: There is a significant disproportionality signal of Raynaud’s phenomenon with CGRP-targeting. This signal stands out when CGRP-targeting drugs are compared to other drugs used in patients with migraine. This study is limited by missing data in pharmacovigilance reports. CGRP-targeting drugs may be subject to Weber effect and reporting bias. Nonetheless, CGRP blockade might be the last straw that disrupts the physiological balance of vascular response in patients at-risk of Raynaud’s phenomenon. Pending further data regarding vascular safety of CGRP-targeting drugs, caution is warranted in these patients.

28 April 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
Alexandre O. GérardAlexandre O. Gérard
Alexandre O. Gérard
SBSusana Barbosa
Susana Barbosa
NPNadège Parassol
Nadège Parassol
MAMarine Andreani
Marine Andreani
Diane A. MerinoDiane A. Merino
Diane A. Merino
FCFrench Network Of Pharmacovigilance Centers
French Network Of Pharmacovigilance Centers
Background: Immune checkpoint inhibitors (ICIs) foster anti-cancer immune responses. Their efficacy comes at the cost of immune-related adverse events (IRAEs). The latter affects various organs, including kidneys, mostly as acute tubulointerstitial nephritis, the pathophysiology of which remains unclear. We conducted a multicentre case–control study to compare the characteristics of patients with renal IRAEs (ICI-AKI) with those of patients diagnosed with other IRAEs. Methods: We queried the French pharmacovigilance database for all adverse events involving ICIs. Reports were classified as ICI-AKI or extrarenal IRAE. For each ICI-AKI report, four reports of extrarenal IRAEs were randomly included (control group, 4:1 ratio). Variables showing an association with a P < 0.05 were included as covariates in a multivariate analysis. Results: Therefore, 167 ICI-AKI reports were compared with 668 extrarenal IRAEs. At least one concomitant extrarenal IRAE was mentioned in 44.3% of ICI-AKI reports. Patients with ICI-AKI were significantly older than patients with extrarenal IRAEs (69.1 versus 64.6 years; P = 0.0135), and chronic kidney disease was significantly more prevalent (12.0% versus 3.3%; P = 0.0125). Patients with ICI-AKI were significantly more likely to be treated with fluindione [adjusted odds ratio (OR) 6.53, 95% confidence interval (95% CI) 2.21–19.31; P = 0.0007], a non-steroidal anti-inflammatory drug (NSAID, OR 3.18, 95% CI 1.07–9.4; P = 0.0368) or a proton-pump inhibitor (PPI, OR 2.18, 95% CI 1.42–3.34; P = 0.0004). Conclusion: This study is limited by a lack of data, preventing confirmation of numerous reports therefore not included in the analysis. We are unable to draw definite pathophysiological conclusions from our data. Nonetheless, we suggest that ICIs may be a ‘second-hit’ that precipitates acute kidney injury caused by another concomitant drug (fluindione, NSAID or PPI).

1 February 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
AFAudrey Fresse
Audrey Fresse
DVDelphine Viard
Delphine Viard
SRSerena Romani
Serena Romani
Alexandre O. GérardAlexandre O. Gérard
Alexandre O. Gérard
MLMarion Lepelley
Marion Lepelley
MDMilou-Daniel Drici
Milou-Daniel Drici